Support for ending and managing HIV

Australian Government Department of Health, 29 November 2018

The Australian Government is strengthening its commitment to ending HIV with the announcement of funding for a new strategy that aims to virtually eliminate the transmission of HIV, the approval of the first HIV self-testing kit and the listing of a new medicine on the PBS.

The first HIV self-testing kit, the Atomo Self Test was approved for use by the TGA yesterday. The test is a single-use rapid finger stick test for the detection of antibodies to HIV and will enable people to test for HIV in their own home.

This will make testing accessible and convenient especially for people that need to test frequently or do not test at all.

The medicine Juluca® (dolutegravir and rilpivirine), which works to stop the replication of the HIV virus, will be listed on the PBS on December 1, which is World AIDS Day.

 

Clinical Education Forum Recording: Contraception Update

SHINE SA, November 2018

Clinicians:  SHINE SA is pleased to present the following Clinical Forum by Dr Amy Moten on the topic of Contraception.

This recording is available free of charge, and access is limited to three months only.

This forum covers emergency contraception and new formulations of the Pill.

3 Category 2 RACGP Points can be awarded on completion of the forum.

Recording length: 1 hour 18 minutes

Barriers to HIV testing for people born in Southeast Asia & sub-Saharan Africa

Curtin University,  2017

Over the past decade Australia has seen an increase in HIV notifications among people born in sub-Saharan Africa (SSA) and South East Asia (SEA).

People born in these regions have the highest rates of HIV diagnosis by region of birth and are overrepresented in late or advanced presentations of HIV infection.

Previous research indicates that migrants from SSA and SEA attend health services in Australia regularly, but only 50% have ever tested for HIV.

This report provides a brief overview of the preliminary results from the Barriers to HIV
testing project – a qualitative research project using focus groups and in-depth interviews to explore the barriers and enablers to HIV testing among priority communities born in SSA and SEA, to better understand the factors influencing late
diagnosis.

HIV PrEP available on PBS in Australia from 1 April / Links to Clinical Resources

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), 21 March 2018

ASHM congratulates the Federal Health Minister, the Hon. Greg Hunt’s announcement of a landmark in HIV prevention to approve HIV-prevention drugs – tenofovir with emtricitabine, known as PrEP – on the Pharmaceutical Benefits Scheme from 1 April, thereby providing broader access for any doctor or general practitioner to be able prescribe PrEP to an Australian resident who holds a current Medicare card.

“The public health benefits are clear, undeniable and transformative benefiting individuals at medium- to high-risk of HIV infection and towards driving a substantial reduction in HIV transmissions in Australia,” said ASHM President, Associate Professor Bloch.

Access Links to Clinical Resources supporting the HIV workforce

  • The definitions of risk for HIV, guidelines and procedures for the appropriate administration and monitoring of PrEP can be found here: ASHM HIV pre-exposure prophylaxis: clinical guidelines
  • The Australian Federation of AIDS Organisations (AFAO) and ASHM have produced a PrEP Fact Sheet to assist PrEP users and people with an interest in using PrEP to understand what subsidised access to PrEP through the PBS means. Access the factsheet here
  • ASHM continues to support the workforce to ensure access to PrEP and best practice in guidelines, training and resources. Access information here
  • The Pharmaceutical Society of Australia has a range of training to support pharmacists in preparing for PrEP on the PBS: www.psa.org.au

 

Push to dispel myths about long-lasting contraception

Guardian Australia, Tuesday 26 September 2017 

Misplaced concerns and myths about long-acting reversible contraceptives have prompted medical experts to release Australia’s first consensus statement, saying they are more reliable and effective than condoms or the pill.

Despite their safety, efficacy and widespread use internationally, the uptake of long-acting reversible contraceptives (LARCs) is low in Australia. On Tuesday the Australian Healthcare and Hospitals Association released a consensus statement – endorsed by 18 agencies, including SHINE SA – on the use of LARCs.

Australia leads the world in hepatitis C treatment – what’s behind its success?

The Conversation, July 31, 2017 4.05pm AEST

The World Health Organisation recently set ambitious goals for the “elimination of hepatitis C as a major public health threat”. These included having 80% of people treated and an 80% reduction in the spread of the virus by 2030. Given there are around 70 million people infected with hep C worldwide, only 20% diagnosed, and no effective vaccine, the task ahead is enormous.

But Australia is impressively heading towards these targets and may present a model for other countries to adopt. A recent report by the Kirby Institute estimated Australia was on track to eliminate hepatitis C by 2026 – four years earlier than the WHO goal.